Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

BJU International

Volumn 105, Issue 11, 2010, Pages 1541-1547

  Moreira, Daniel M ^a,b   Presti Jr , Joseph C ^d   Aronson, William J ^e,f   Terris, Martha K ^g   Kane, Christopher J ^h   Amling, Christopher L ⁱ   Freedland, Stephen J ^a,b,c  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER GROWTH; CANCER STAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SEMINAL VESICLE;

DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77952190483     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09016.x     Document Type: Article

References (25)

1. Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004 101 : 2549 2556
2. Valicenti RK, Gomella LG, Ismail M et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology 1998 52 : 1034 1040 (Pubitemid 28533373)
3. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004 291 : 1325 1332 (Pubitemid 38541647)
4. Taylor JA III, Koff SG, Dauser DA, McLeod DG. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int 2006 98 : 540 543 (Pubitemid 44185872)
5. Hamilton RJ, Aronson WJ, Presti JC et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer 2007 110 : 2202 2209
6. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003 61 : 365 369 (Pubitemid 36206534)
7. Jayachandran J, Banez LL, Levy DE et al. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol 2008 179 : 1791 1796
8. Cookson MS, Aus G, Burnett AL et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007 177 : 540 545 (Pubitemid 46054056)
9. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994 81 : 515 526
10. Kang DE, Fitzsimons NJ, Presti JC et al. Risk stratification of men with Gleason score 7-10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology 2007 70 : 277 282
11. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2009 [Epub ahead of print], DOI:10.1016/j.eururo.2009.03.077
12. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 1597 (Pubitemid 29211767)
13. Song DY, Thompson TL, Ramakrishnan V et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002 60 : 281 287 (Pubitemid 34831773)
14. Nakamura M, Hasumi H, Miyoshi Y et al. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol 2005 12 : 1050 1054 (Pubitemid 43110217)
15. Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005 173 : 777 780 (Pubitemid 40239340) (Pubitemid 40239340) (Pubitemid 40239340)
16. Sakai I, Harada K, Kurahashi T et al. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Urol Int 2006 76 : 227 231
17. Doherty AP, Bower M, Smith GL et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000 83 : 1432 1436
18. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L. J Urol 1997 157 : 913 8
19. Swanson GP, Hussey MA, Tangen CM et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007 25 : 2225 2229
20. Moreira DM, Presti JC, Aronson WJ et al. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol 2009 182 : 2250 2256
21. Vassilikos EJ, Yu H, Trachtenberg J et al. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clin Biochem 2000 33 : 115 123 (Pubitemid 30212819)
22. Nielsen ME, Han M, Mangold L et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol 2006 176 : 515 519 (Pubitemid 43927881)
23. Arai Y, Okubo K, Aoki Y, Maekawa S, Okada T, Maeda H. Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy. Int J Urol 1998 5 : 550 555 (Pubitemid 29008052)
24. Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 1997 50 : 573 579
25. Naselli A, Introini C, Andreatta R, Spina B, Truini M, Puppo P. Prognostic factors of persistently detectable PSA after radical prostatectomy. Int J Urol 2009 16 : 82 6